Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Total Liabilities (2022 - 2025)

Gossamer Bio's Total Liabilities history spans 4 years, with the latest figure at $295.0 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 3.22% year-over-year to $295.0 million; the TTM value through Dec 2025 reached $295.0 million, up 3.22%, while the annual FY2025 figure was $295.0 million, 3.22% up from the prior year.
  • Total Liabilities reached $295.0 million in Q4 2025 per GOSS's latest filing, up from $291.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $296.7 million in Q3 2024 to a low of $232.6 million in Q1 2024.
  • Average Total Liabilities over 4 years is $269.2 million, with a median of $265.9 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: dropped 8.94% in 2023, then increased 23.3% in 2025.
  • A 4-year view of Total Liabilities shows it stood at $260.4 million in 2022, then decreased by 4.31% to $249.1 million in 2023, then grew by 14.71% to $285.8 million in 2024, then grew by 3.22% to $295.0 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Total Liabilities are $295.0 million (Q4 2025), $291.2 million (Q3 2025), and $287.0 million (Q2 2025).